Deferred Tax Assets, Valuation Allowance in USD of Checkpoint Therapeutics, Inc. from Q4 2015 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Checkpoint Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and change rate from Q4 2015 to Q4 2024.
  • Checkpoint Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $89.4M, a 2.46% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Checkpoint Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed
Q4 2024 $89.4M +$2.15M +2.46% 31 Dec 2024 10-K 28 Mar 2025
Q4 2023 $87.3M +$22.5M +34.8% 31 Dec 2023 10-K 28 Mar 2025
Q4 2022 $64.7M +$13.3M +25.8% 31 Dec 2022 10-K 22 Mar 2024
Q4 2021 $51.5M +$14.2M +38% 31 Dec 2021 10-K 31 Mar 2023
Q4 2020 $37.3M +$5.54M +17.5% 31 Dec 2020 10-K 28 Mar 2022
Q4 2019 $31.7M +$6.68M +26.7% 31 Dec 2019 10-K 12 Mar 2021
Q4 2018 $25.1M +$6.03M +31.7% 31 Dec 2018 10-K 11 Mar 2020
Q4 2017 $19M +$6.63M +53.4% 31 Dec 2017 10-K 18 Mar 2019
Q4 2016 $12.4M +$7.94M +178% 31 Dec 2016 10-K 16 Mar 2018
Q4 2015 $4.46M 31 Dec 2015 10-K 21 Mar 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.